New Study Shows Rapid EGFR testing with Idylla!
Products are for professional/laboratory use only.
Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
Products are for professional/laboratory use only.
Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
Products are for professional/laboratory use only.
Press Release: Mechelen, Belgium, 27 June 2018
Products are for professional/laboratory use only.
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).
Products are for professional/laboratory use only.
A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).
Products are for professional/laboratory use only.
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.